

%under or above expected
50
40
30
20
10
0
-10
-20
-30
-40
-50
0.03125
0.0625
0.125
0.25
0.5
1.0
Compound 1 (nM)
2.0
0.5
0.125
Compound 2 (nM)
10 to 15
5 to 10
0 to 5
-5 to 0

Figure 1



1.00
0.806
0.613
0.419
0.225
0.031
Compound 1 (nM)
0.13
0.90
1.68
2.45
3.23
4.0
Compound 2 (nM)
antagonistic
additive
synergistic

Figure 2



% under or above expected
20
15
10
5
0
-5
-10
-15
-20
1.97E-04
3.94E-04
7.88E-04
1.58E-03
3.15E-03
6.30E-03
Compound 4 (nM)
0.375
0.0938
0.0234
Compound 1 (nM)
15 to 20
10 to 15
5 to 10
0 to 5
-5 to 0
-10 to -5
-15 to -10
-20 to -15

Figure 3



0.750
0.605
0.459
0.314
0.169
0.023
Compound 1 (nM)
0.0002
0.0014
0.0026
0.0039
0.0051
0.0063
Compound 4 (nM)
antagonistic
additive
synergistic

Figure 4



Percent of cells that survived
1
0.75
0.5
0.25
0
>1
>1
0.48
> 0.1
0.005
0.03
0.005
0.003
0.001
0
0
0
0
#1 = compound 1
#2 = compound 2
#4 = compound 4
10X #4
10X #2
10X #1
100X #4
100X #2
100X #1
10X #4 + 10X #2
10X #4 + 10X #1
10X #2 + 10X #1
100X #4 + 100X #2
100X #4 + 100X #1
100X #2 + 100X #1
10X #4 + 10X #2 + 10X #1

Figure 5A



Frequency of resistant colonies (%)
0.0050
0.0040
0.0030
0.0020
0.0010
0.0000
< 0.0001
10X Compound 2 + 10X Compound 4
10X Compound 1 + 10X Compound 4
10X Compound 1 + 10X Compound 2
Triple Combinations, 5X or 10X each

Figure 5B



1a-H77
Log decrease in HCV RNA
1
0
-1
-2
-3
-4
-5
-6
-7
Limit of detection
0
1
2
3
4
5
6
Passage number
DMSO
10X Compound 1
10X Compound 4
100X Compound 1
100X Compound 4
10X Compound 1 + 10X Compound 4

Figure 5C



1b-Con1
Log decrease in HCV RNA
1
0
-1
-2
-3
-4
-5
-6
-7
Limit of detection
0
1
2
3
4
5
6
Passage number
DMSO
10X Compound 1
10X Compound 4
100X Compound 1
100X Compound 4
10X Compound 1 + 10X Compound 4

Figure 5D



150 mg QD Compound 1 + 400 mg BID Compound 2
250 mg QD Compound 1 + 400 mg BID Compound 2
% SVR
0
20
40
60
80
100
6
8
10
12
16
24
Time (weeks)

Figure 6A



150 mg QD Compound 1 + 25 mg QD Compound 4
250 mg QD Compound 1 + 25 mg QD Compound 4
% SVR
0
20
40
60
80
100
6
8
10
12
16
24
Time (weeks)

Figure 6B



150 mg QD Compound 1 + 400 mg BID Compound 2 + 25 mg QD Compound 4
250 mg QD Compound 1 + 400 mg BID Compound 2 + 25 mg QD Compound 4
% SVR
0
20
40
60
80
100
6
8
10
12
16
24
Time (weeks)

Figure 6C



150 mg Compound 1 + 400 mg Compound 3 (predicted)
150 mg Compound 1 + 400 mg Compound 3 (observed)
% LOD
0
20
40
60
80
100
2
4
8
10
12
Time (weeks)

Figure 7



Observed %SVR
Model Predicted %SVR
% SVR
0
20
40
60
80
100
150 mg QD Compound 1 +
400 mg BID Compound 2
250 mg QD Compound 1 +
400 mg BID Compound 2

Figure 8



BMS-790052 (60mg QD)+ BMS-650032 (600 mg BID)
% SVR
0
20
40
60
80
100
8
10
12
16
20
24
Weeks

Figure 9




Figure 10




Figure 11

PSI-7977 + Daclatasvir




Figure 12



TMC-435+PSI-7977
Prediced % SVR
0
20
40
60
80
100
6
8
10
12
16
24
Time (weeks)

Figure 13



Danoprevir+Mercitabine
Predicted % SVR
0
20
40
60
80
100
8
10
12
16
24
Time (weeks)

Figure 14



GS-9451 + GS-9190 + GS-5885
Predicted % SVR
0
20
40
60
80
100
8
12
24
Time (weeks)

Figure 15



GS-9451 + GS-7977
GS-5885 + GS-7977
GS-9451 + GS-5885 + GS-7977
Predicted % SVR
0
20
40
60
80
100
8
12
24
Time (weeks)

Figure 16



TMC-435 + Daclatasvir
Prediced % SVR
0
20
40
60
80
100
8
12
16
20
24
Time (weeks)

Figure 17